An acute lymphoblastic leukemia cell-based preclinical assay
revealed functional differences of commercial L-asparaginase
administered in Colombia
Diego Fernando Rincón Reyes1,4 | José Luis
Padilla Agudelo1,4 | Andrea Isabel Pinilla Da
Silva1 | Diana Marcela Ortega
Quintero1,3 | Diana Lorena Valencia
Libreros2 | Agustín Darío Contreras
Acosta2** | José Arturo Gutiérrez
Triana1*
- Immunology and Molecular Epidemiology Research Group (GIEM). Escuela
de Microbiología, Facultad de Salud. Universidad Industrial de
Santander, Colombia
- Asociación Colombiana de Hematología y Oncología Pediátrica (ACHOP),
Colombia
- Clinical Laboratory. Universidad Industrial de Santander, Colombia
- These authors contributed equally to this work.
Corresponding authors:*José Arturo Gutiérrez Triana, Immunology and Molecular
Epidemiology Research Group (GIEM). School of Microbiology, Faculty of
Health. Universidad Industrial de Santander. Carrera 32 N29-31,
Bucaramanga, Colombia. Phone +57 (7) 6344000 ext. 3163. Fax +57 (6221)
54-5639. Email:jagutri@uis.edu.co**Agustín Darío Contreras Acosta, Asociación Colombiana de
Hematología y Oncología Pediátrica. Carrera 23 N134A-66. Bogotá,
Colombia. Phone +57 3138535181. Email:info@achop.org
Text word count 1181;
Abstract word count: 100;
Brief running title: Preclinical assay of L-ASNase in B-ALL
cells
Key words: L-asparaginase, NALM-6, B-ALL, preclinical assay,
medicament activity.
Tables: 0
Figures: 1